Table 3.

Summary of serious treatment-emergent adverse events during the open-label treatment period

n (%) of patients	Evinacumab-naïve n = 46	Evinacumab-continue n = 70	Total n = 116
Angina pectoris	0	2 (2.9)	2 (1.7)
Angina unstable	0	2 (2.9)	2 (1.7)
Aortic valve disease	0	2 (2.9)	2 (1.7)
Chest pain	0	2 (2.9)	2 (1.7)
Coronary artery disease	0	2 (2.9)	2 (1.7)
Acute myocardial infarction	0	1 (1.4)	1 (0.9)
Aortic stenosis	0	1 (1.4)	1 (0.9)
Arteriosclerosis	0	1 (1.4)	1 (0.9)
Arteriovenous fistula-site complication	1 (2.2)	0	1 (0.9)
Atrial fibrillation	1 (2.2)	0	1 (0.9)
Cardiac arrest	1 (2.2)	0	1 (0.9)
Cardiac failure acute	0	1 (1.4)	1 (0.9)
Cardiac failure chronic	1 (2.2)	0	1 (0.9)
Cardiac valve disease	1 (2.2)	0	1 (0.9)
Cataract	0	1 (1.4)	1 (0.9)
Cervical vertebral fracture	0	1 (1.4)	1 (0.9)
Coronary artery occlusion	0	1 (1.4)	1 (0.9)
Coronary artery stenosis	0	1 (1.4)	1 (0.9)
Food allergy	0	1 (1.4)	1 (0.9)
Gastroenteritis	1 (2.2)	0	1 (0.9)
Glaucoma	0	1 (1.4)	1 (0.9)
Hepatitis acute	0	1 (1.4)	1 (0.9)
Intestinal ischaemia	0	1 (1.4)	1 (0.9)
Ischaemic stroke	0	1 (1.4)	1 (0.9)
Mental status changes	0	1 (1.4)	1 (0.9)
Myocardial infarction	0	1 (1.4)	1 (0.9)
Oesophageal candidiasis	0	1 (1.4)	1 (0.9)
Ovarian cyst ruptured	1 (2.2)	0	1 (0.9)
Peripheral artery stenosis	1 (2.2)	0	1 (0.9)
Pneumonia	1 (2.2)	0	1 (0.9)
Prostate cancer	0	1 (1.4)	1 (0.9)
Renal infarct	0	1 (1.4)	1 (0.9)
Rib fracture	0	1 (1.4)	1 (0.9)
Spinal epidural haematoma	0	1 (1.4)	1 (0.9)
Scapula fracture	0	1 (1.4)	1 (0.9)
Supravalvular aortic stenosis	0	1 (1.4)	1 (0.9)
Vascular pseudoaneurysm	1 (2.2)	0	1 (0.9)

SAE, serious adverse event; TEAE, treatment-emergent adverse event.